Recombinant Human LILRB1/CD85j/ILT2 His-tag Protein, CF
Recombinant Human LILRB1/CD85j/ILT2 His-tag Protein, CF Summary
Product Specifications
| Human LILRB1 (Gly24-His458) Accession # Q8NHL6 | HHHHHH |
| N-terminus | C-terminus |
Analysis
Product Datasheets
Carrier Free
CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
8989-T2
| Formulation | Lyophilized from a 0.2 μm filtered solution in PBS. |
| Reconstitution | Reconstitute at 100 μg/mL in PBS. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage: | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Scientific Data
View Larger
When Recombinant Human LILRB1/CD85j/ILT2 His-tag (Catalog # 8989-T2) is coated at 2 µg/mL, Recombinant Human Angiopoietin-like Protein 7/ANGPTL7 (914-AN) binds with a typical ED50 of 0.02-0.2 μg/mL.
Reconstitution Calculator
Background: LILRB1/CD85j/ILT2
LILRB1, also known as CD85j and ILT2, is a 110 kDa transmembrane glycoprotein in the LILR immunoregulatory protein family (1). Mature human LILRB1 consists of a 438 amino acid (aa) extracellular domain (ECD) with 4 tandem Ig-like domains, a 21 aa transmembrane segment, and a 168 aa cytoplasmic domain with 4 inhibitory ITIM motifs (2). Alternative splicing generates an additional isoform that lacks the transmembrane and cytoplasmic regions (3). LILRB1 is expressed on the surface of B cells and monocytes, as well as subsets of NK cells, memory/effector CD8+ T cells, gamma δ T cells, and monocyte-derived dendritic cells (3-7). LILRB1 binds to MHC-I as well as non-classical MHC-I molecules (e.g. HLA-F, HLA-G, and HLA-B27) and the MHC-I mimetic UL18 encoded by cytomegalovirus (3, 5, 8-10). R&D Systems
in-house testing indicates that LILRB1 also binds to Angiopoietin-like 7. Ligation of LILRB1 inhibits the antigen induced proliferation and activation of CD8+ T cells, CD4+ T cells, NK cells, and gamma δ T cells (3, 4, 11-13). On dendritic cells, ligation inhibits the production of IL-10, IL-12p70, and TGF-beta and protects from Fas-mediated apoptosis (7).
- Thomas, R. et al. (2010) Clin. Rev. Allergy Immunol. 38:159.
- Samaridis, J. and M. Colonna (1997) Eur. J. Immunol. 27:660.
- Colonna, M. et al. (1997) J. Exp. Med. 186:1809.
- Harly, C. et al. (2011) Blood 117:2864.
- Cosman, D. et al. (1997) Immunity 7:273.
- Young, N.T. et al. (2001) J. Immunol. 166:3933.
- Young, N.T. et al. (2008) Blood 111:3090.
- Lepin, E.J.M. et al. (2000) Eur. J. Immunol. 30:3552.
- Shiroishi, M. et al. (2003) Proc. Natl. Acad. Sci. USA 100:8856.
- Allen, R.L. et al. (2001) J. Immunol. 167:5543.
- Ince, M.N. et al. (2004) Immunology 112:531.
- Saverino, D. et al. (2000) J. Immunol. 165:3742.
- Saverino, D. et al. (2002) J. Immunol. 168:207.
Citations for Recombinant Human LILRB1/CD85j/ILT2 His-tag Protein, CF
R&D Systems personnel manually curate a database that contains references using R&D Systems products. The data collected includes not only links to publications in PubMed, but also provides information about sample types, species, and experimental conditions.
2
Citations: Showing 1 - 2
Filter your results:
Filter by:
-
ILT2 and ILT4 drive myeloid suppression via both overlapping and distinct mechanisms
Authors: Tian, J;Ashique, AM;Weeks, S;Lan, T;Yang, H;Chen, HH;Song, C;Koyano, K;Mondal, K;Tsai, D;Cheung, I;Moshrefi, M;Kekatpure, A;Fan, B;Li, B;Qurashi, S;Rocha, L;Aguayo, J;Rodgers, C;Meza, M;Heeke, D;Medfisch, SM;Chu, C;Starck, S;Basak, NP;Sankaran, S;Malhotra, M;Crawley, S;Tran, TT;Duey, DY;Ho, C;Mikaelian, I;Liu, W;Rivera, LB;Huang, J;Paavola, KJ;O'Hollaren, K;Blum, LK;Lin, VY;Chen, P;Iyer, A;He, S;Roda, JM;Wang, Y;Sissons, J;Kutach, AK;Kaplan, DD;Stone, GW;
Cancer immunology research
Species: Mouse
Sample Types: Lung Perfusate
Applications: In Vivo -
Macrophage Biomarkers sCD163 and sSIRPalpha in Serum Predict Mortality in Sarcoma Patients
Authors: N Aggerholm-, HN Friis, T Baad-Hanse, HJ Møller, B Sandfeld-P
Cancers, 2023-02-28;15(5):.
Species: Human
Sample Types: Serum
Applications: Reference Standard
FAQs
No product specific FAQs exist for this product, however you may
View all Proteins and Enzyme FAQsReviews for Recombinant Human LILRB1/CD85j/ILT2 His-tag Protein, CF
Average Rating: 4.5 (Based on 2 Reviews)
Have you used Recombinant Human LILRB1/CD85j/ILT2 His-tag Protein, CF?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Filter by:
Reason for Rating: Confirmed binding of ILT2 and HLA-G reagent. Binding is weak so not able to obtain affinity and kinetic measurements. But did see specific binding to ILT2 compared with control
immobilize HLA-G and flow ILT2-his
Reason for Rating: good material
Performed binding specificity experiments for the lead molecule (xLILRA6) on its ligand family panels (RA1, RA2, RA5, RA6, RB1, RB2, RB3, RB4, RB5)
